Lexaria Bioscience to Receive New Patents in Four Markets
Global innovator in drug delivery platforms, Lexaria Bioscience (Nasdaq: LEXX), has received notifications of four new patents either awarded or allowed. The new patents cover Japan, Australia, Canada and the United States.
Lexaria believes that its US patent, Compositions and Methods for Treating Hypertension, could be of particular importance in relation to its expected upcoming FDA Investigational New Drug (IND) application.
In Japan, Lexaria has received a new patent under its Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents.
In Australia, the company received a new patent under its Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents.
In Canada, a new patent under Lexaria’s Patent Family #8: Compositions Infused With Nicotine Compounds and Methods of Use Thereof has been allowed.
In the US, a new patent under Patent Family #21: Compositions and Methods for Treating Hypertension has been allowed.
After the awarding of these patents, Lexaria’s total patent portfolio will have grown to 32 granted patents worldwide.
About Lexaria Bioscience
Lexaria Bioscience’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide.